EcoDrugPlus

Cholesterol 24-Hydroxylase-Like

Ensembl ID : ENSSTUG00000029488
Gene Symbol: LOC115175113
2 Cross references
244 Possible Orthologues:

Cholesterol 24-Hydroxylase-Like

Ensembl ID : ENSSTUG00000029200
Gene Symbol: LOC115175200
2 Cross references
244 Possible Orthologues:

Cholesterol 24-Hydroxylase-Like

Ensembl ID : ENSSTUG00000026018
Gene Symbol: LOC115157569
2 Cross references
240 Possible Orthologues:

Cholesteryl Ester Transfer Protein, Plasma

Ensembl ID : ENSSTUG00000026020
Gene Symbol: CETP
1 Cross references
131 Possible Orthologues:

Cholesteryl Ester Transfer Protein-Like

Ensembl ID : ENSSTUG00000010672
Gene Symbol: LOC115196824
3 Cross references
132 Possible Orthologues:

Cholinergic Receptor Muscarinic 3

Ensembl ID : ENSSTUG00000047462
Gene Symbol: CHRM3
1 Cross references
182 Possible Orthologues:

Cholinergic Receptor Muscarinic 3

Ensembl ID : ENSSTUG00000045110
Gene Symbol: CHRM3
3 Cross references
182 Possible Orthologues:

Cholinergic Receptor Muscarinic 3

Ensembl ID : ENSSTUG00000035715
Gene Symbol: CHRM3
3 Cross references
182 Possible Orthologues:

Cholinergic Receptor Muscarinic 4

Ensembl ID : ENSSTUG00000009805
Gene Symbol: CHRM4
3 Cross references
181 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 3 Subunit

Ensembl ID : ENSSTUG00000010913
Gene Symbol: CHRNA3
3 Cross references
195 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 3 Subunit

Ensembl ID : ENSSTUG00000040462
Gene Symbol: CHRNA3
3 Cross references
196 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 4 Subunit

Ensembl ID : ENSSTUG00000031023
Gene Symbol: CHRNA4
3 Cross references
136 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).